You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlprenolol
Accession NumberDB00866  (APRD00736)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionOne of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Structure
Thumb
Synonyms
(RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol
1-(2-Allylphenoxy)-3-isopropylamino-2-propanol
1-(O-Allylphenoxy)-3-(isopropylamino)-2-propanol
Alfeprol
Alprenolol
Alprénolol
Alprenolol
Alprenololum
Aprenololo
External Identifiers
  • H 56/28
  • H 561/28
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ApllobalAstraZeneca
AptinAstraZeneca
AptineNot Available
Aptol DurilesNot Available
AtenenolTsuruhara Seiyaku
ElpShyh Dar
GubernalNot Available
RegletinNot Available
SkajilolKotobuki Seiyaku
YobirNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Alprenolol hydrochloride
ThumbNot applicableDBSALT000932
Categories
UNII877K5MQ27W
CAS number13655-52-2
WeightAverage: 249.3486
Monoisotopic: 249.172878985
Chemical FormulaC15H23NO2
InChI KeyInChIKey=PAZJSJFMUHDSTF-UHFFFAOYSA-N
InChI
InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
IUPAC Name
1-[2-(prop-2-en-1-yl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC=C1CC=C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropenes. These are compounds containing a phenylpropene moiety, which consists of a propene substituent bound to a phenyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropenes
Direct ParentPhenylpropenes
Alternative Parents
Substituents
  • Phenylpropene
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, angina, and arrhythmia
PharmacodynamicsAlprenolol is a non-selective beta-blocker used in the treatment of hypertension, edema, ventricular tachycardias, and atrial fibrillation. Alprenolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Alprenolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Alprenolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, alprenolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionAlprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding80-90%
Metabolism

Hepatic. One of the active metabolites, 4-OH-alprenolol, is an active beta-blocker.

SubstrateEnzymesProduct
Alprenolol
Not Available
4-hydroxy-alprenololDetails
Route of eliminationNot Available
Half life2-3 hours
ClearanceNot Available
ToxicityLD50=597.0 mg/kg (Orally in rats)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Alprenolol Action PathwayDrug actionSMP00297
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9831
Blood Brain Barrier-0.9394
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6064
P-glycoprotein inhibitor IInhibitor0.5066
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8305
CYP450 2C9 substrateNon-substrate0.824
CYP450 2D6 substrateSubstrate0.882
CYP450 3A4 substrateNon-substrate0.7469
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8839
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9106
BiodegradationNot ready biodegradable0.9646
Rat acute toxicity2.5069 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8664
hERG inhibition (predictor II)Non-inhibitor0.6946
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3466376 No1966-06-171986-06-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point107-109 °CPhysProp
water solubility547 mg/LNot Available
logP3.10HANSCH,C ET AL. (1995)
Caco2 permeability-4.62ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP2.59ALOGPS
logP2.69ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability29.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (3.94 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

http://www.google.com.mx/patents/US3466376

General References
  1. Hold KM, de Boer D, Bos KL, van Ooijen RD, Zuidema J, Maes RA: Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. J Chromatogr Sci. 1996 Jan;34(1):13-9. [PubMed:8586675 ]
  2. Himori N, Ishimori T, Izumi A, Hiramatsu Y: Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. [PubMed:15525 ]
External Links
ATC CodesC07AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (28.7 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Alprenolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Alprenolol.
AbirateroneThe metabolism of Alprenolol can be decreased when combined with Abiraterone.
AcebutololAlprenolol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Alprenolol.
AcepromazineAcepromazine may increase the hypotensive activities of Alprenolol.
AcetohexamideAlprenolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Acetylcholine.
AcetyldigitoxinAlprenolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Alprenolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Alprenolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Alprenolol.
AlfuzosinAlprenolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Alprenolol.
AliskirenAlprenolol may increase the hypotensive activities of Aliskiren.
AmbenoniumAmbenonium may increase the bradycardic activities of Alprenolol.
AmbrisentanAlprenolol may increase the hypotensive activities of Ambrisentan.
AmifostineAlprenolol may increase the hypotensive activities of Amifostine.
AminophyllineAlprenolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Alprenolol.
AmlodipineAmlodipine may increase the hypotensive activities of Alprenolol.
AmobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Amobarbital.
AmodiaquineThe metabolism of Alprenolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Alprenolol can be increased when it is combined with Amoxapine.
AntipyrineAntipyrine may decrease the antihypertensive activities of Alprenolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
ApraclonidineApraclonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
ApremilastApremilast may decrease the antihypertensive activities of Alprenolol.
ArbutamineAlprenolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Arecoline.
ArformoterolAlprenolol may decrease the bronchodilatory activities of Arformoterol.
ArtemetherThe metabolism of Alprenolol can be decreased when combined with Artemether.
AtenololAtenolol may increase the hypotensive activities of Alprenolol.
AtomoxetineThe metabolism of Alprenolol can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Alprenolol.
AzelastineAzelastine may decrease the antihypertensive activities of Alprenolol.
BalsalazideBalsalazide may decrease the antihypertensive activities of Alprenolol.
BambuterolAlprenolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Alprenolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Alprenolol.
BenmoxinBenmoxin may increase the hypotensive activities of Alprenolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Alprenolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
BepridilAlprenolol may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Alprenolol.
BethanecholThe risk or severity of adverse effects can be increased when Alprenolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Alprenolol.
BimatoprostAlprenolol may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Alprenolol.
BosentanBosentan may increase the hypotensive activities of Alprenolol.
BretyliumAlprenolol may increase the hypotensive activities of Bretylium.
BrimonidineAlprenolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Alprenolol.
BromfenacBromfenac may decrease the antihypertensive activities of Alprenolol.
BromocriptineAlprenolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Alprenolol.
BupranololAlprenolol may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Alprenolol can be decreased when combined with Bupropion.
CabergolineAlprenolol may increase the vasoconstricting activities of Cabergoline.
CandesartanCandesartan may increase the hypotensive activities of Alprenolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Alprenolol.
CaptoprilAlprenolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Alprenolol is combined with Carbachol.
CaroxazoneCaroxazone may increase the hypotensive activities of Alprenolol.
CarprofenCarprofen may decrease the antihypertensive activities of Alprenolol.
CarteololCarteolol may increase the hypotensive activities of Alprenolol.
CarvedilolAlprenolol may increase the hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Alprenolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Alprenolol.
CeliprololCeliprolol may increase the hypotensive activities of Alprenolol.
CeliprololAlprenolol may decrease the bronchodilatory activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Alprenolol.
ChlorothiazideAlprenolol may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Alprenolol.
ChlorpropamideAlprenolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Alprenolol.
CholecalciferolThe metabolism of Alprenolol can be decreased when combined with Cholecalciferol.
CilazaprilAlprenolol may increase the hypotensive activities of Cilazapril.
CimetidineThe metabolism of Alprenolol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Alprenolol can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Alprenolol can be decreased when combined with Citalopram.
ClemastineThe metabolism of Alprenolol can be decreased when combined with Clemastine.
ClenbuterolAlprenolol may decrease the bronchodilatory activities of Clenbuterol.
ClobazamThe metabolism of Alprenolol can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Alprenolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Alprenolol.
ClonixinClonixin may decrease the antihypertensive activities of Alprenolol.
ClotrimazoleThe metabolism of Alprenolol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Alprenolol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Alprenolol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Alprenolol can be decreased when combined with Cocaine.
CoumaphosCoumaphos may increase the bradycardic activities of Alprenolol.
CryptenamineCryptenamine may increase the hypotensive activities of Alprenolol.
CyclothiazideCyclothiazide may increase the hypotensive activities of Alprenolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Alprenolol.
DapoxetineThe serum concentration of Alprenolol can be increased when it is combined with Dapoxetine.
DarifenacinThe metabolism of Alprenolol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Alprenolol can be increased when it is combined with Darunavir.
DebrisoquinAlprenolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Alprenolol.
DelavirdineThe metabolism of Alprenolol can be decreased when combined with Delavirdine.
DemecariumDemecarium may increase the bradycardic activities of Alprenolol.
DeserpidineAlprenolol may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Alprenolol can be decreased when combined with Desipramine.
DeslanosideAlprenolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
DiazoxideDiazoxide may increase the hypotensive activities of Alprenolol.
DichlorvosDichlorvos may increase the bradycardic activities of Alprenolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Alprenolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Alprenolol.
DigitoxinAlprenolol may increase the bradycardic activities of Digitoxin.
DigoxinAlprenolol may increase the bradycardic activities of Digoxin.
DihydroergotamineAlprenolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
DiltiazemDiltiazem may increase the hypotensive activities of Alprenolol.
DiphenhydramineThe metabolism of Alprenolol can be decreased when combined with Diphenhydramine.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Alprenolol.
DipivefrinAlprenolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Alprenolol.
DisopyramideDisopyramide may increase the bradycardic activities of Alprenolol.
DobutamineAlprenolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Alprenolol.
DorzolamideAlprenolol may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Alprenolol.
DronedaroneThe metabolism of Alprenolol can be decreased when combined with Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Alprenolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Alprenolol.
DroxidopaAlprenolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineThe metabolism of Alprenolol can be decreased when combined with Duloxetine.
DyphyllineAlprenolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Alprenolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Alprenolol.
EfonidipineAlprenolol may increase the hypotensive activities of Efonidipine.
EliglustatThe metabolism of Alprenolol can be decreased when combined with Eliglustat.
EnalaprilEnalapril may increase the hypotensive activities of Alprenolol.
EnalaprilatAlprenolol may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Alprenolol.
EphedraAlprenolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Alprenolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
EpinephrineAlprenolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Alprenolol.
EpoprostenolAlprenolol may increase the hypotensive activities of Epoprostenol.
EprosartanAlprenolol may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineAlprenolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineAlprenolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Alprenolol.
EtodolacEtodolac may decrease the antihypertensive activities of Alprenolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Alprenolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.
EtoperidoneThe serum concentration of Alprenolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Alprenolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Alprenolol.
exisulindexisulind may decrease the antihypertensive activities of Alprenolol.
FelodipineAlprenolol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Alprenolol.
FenfluramineThe serum concentration of Alprenolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Alprenolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Alprenolol.
FenoterolAlprenolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Alprenolol.
FingolimodAlprenolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alprenolol.
FlunixinFlunixin may decrease the antihypertensive activities of Alprenolol.
FluoxetineThe serum concentration of Alprenolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Alprenolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Alprenolol.
FluvoxamineThe metabolism of Alprenolol can be decreased when combined with Fluvoxamine.
FormoterolAlprenolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Alprenolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Alprenolol.
GalantamineGalantamine may increase the bradycardic activities of Alprenolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Alprenolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Alprenolol.
GlibornurideAlprenolol may increase the hypoglycemic activities of Glibornuride.
GliclazideAlprenolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideAlprenolol may increase the hypoglycemic activities of Glimepiride.
GlipizideAlprenolol may increase the hypoglycemic activities of Glipizide.
GliquidoneAlprenolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideAlprenolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideAlprenolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Alprenolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Alprenolol.
GuanadrelGuanadrel may increase the hypotensive activities of Alprenolol.
GuanethidineAlprenolol may increase the hypotensive activities of Guanethidine.
GuanfacineAlprenolol may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Alprenolol can be decreased when combined with Haloperidol.
HexamethoniumAlprenolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Hexobarbital.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Alprenolol.
Huperzine AHuperzine A may increase the bradycardic activities of Alprenolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Alprenolol.
HydralazineAlprenolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideAlprenolol may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Alprenolol.
HydroxychloroquineThe metabolism of Alprenolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Alprenolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Alprenolol.
IcatibantIcatibant may decrease the antihypertensive activities of Alprenolol.
IloprostIloprost may increase the hypotensive activities of Alprenolol.
ImipramineThe metabolism of Alprenolol can be decreased when combined with Imipramine.
IndacaterolAlprenolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Alprenolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Alprenolol.
IndenololAlprenolol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Alprenolol can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Alprenolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Alprenolol.
IndoraminAlprenolol may increase the hypotensive activities of Indoramin.
Insulin PorkAlprenolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Alprenolol.
IproniazidIproniazid may increase the hypotensive activities of Alprenolol.
IrbesartanAlprenolol may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Alprenolol.
IsoetarineAlprenolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Alprenolol.
IsoniazidThe metabolism of Alprenolol can be decreased when combined with Isoniazid.
IsoprenalineAlprenolol may decrease the bronchodilatory activities of Isoprenaline.
IsoxicamIsoxicam may decrease the antihypertensive activities of Alprenolol.
IsradipineIsradipine may increase the hypotensive activities of Alprenolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Alprenolol.
KetoconazoleThe metabolism of Alprenolol can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Alprenolol.
KetorolacKetorolac may decrease the antihypertensive activities of Alprenolol.
LabetalolLabetalol may increase the hypotensive activities of Alprenolol.
LacidipineAlprenolol may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Alprenolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Alprenolol.
LercanidipineLercanidipine may increase the hypotensive activities of Alprenolol.
LevomilnacipranThe serum concentration of Alprenolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Alprenolol.
LisinoprilLisinopril may increase the hypotensive activities of Alprenolol.
LobelineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Lobeline.
LofexidineAlprenolol may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Alprenolol can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Alprenolol can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the antihypertensive activities of Alprenolol.
LosartanLosartan may increase the hypotensive activities of Alprenolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Alprenolol.
Lu AA21004The serum concentration of Alprenolol can be increased when it is combined with Lu AA21004.
LumefantrineThe metabolism of Alprenolol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Alprenolol.
MacitentanAlprenolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Alprenolol.
MalathionMalathion may increase the bradycardic activities of Alprenolol.
ManidipineAlprenolol may increase the hypotensive activities of Manidipine.
MasoprocolMasoprocol may decrease the antihypertensive activities of Alprenolol.
MebanazineMebanazine may increase the hypotensive activities of Alprenolol.
MecamylamineMecamylamine may increase the hypotensive activities of Alprenolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Alprenolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Alprenolol.
MefloquineMefloquine may increase the bradycardic activities of Alprenolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Alprenolol.
MemantineMemantine may increase the bradycardic activities of Alprenolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Alprenolol.
MesalazineMesalazine may decrease the antihypertensive activities of Alprenolol.
MesoridazineMesoridazine may increase the hypotensive activities of Alprenolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Alprenolol.
MethacholineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Methacholine.
MethadoneThe metabolism of Alprenolol can be decreased when combined with Methadone.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
MethohexitalThe serum concentration of Alprenolol can be decreased when it is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Alprenolol.
MethyldopaAlprenolol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Alprenolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Alprenolol.
MethylphenobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Methylphenobarbital.
MetipranololAlprenolol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Alprenolol.
MetoprololMetoprolol may increase the hypotensive activities of Alprenolol.
MibefradilAlprenolol may increase the hypotensive activities of Mibefradil.
MidodrineAlprenolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Alprenolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Alprenolol.
MinoxidilMinoxidil may increase the hypotensive activities of Alprenolol.
MirabegronThe metabolism of Alprenolol can be decreased when combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Alprenolol.
MoexiprilMoexipril may increase the hypotensive activities of Alprenolol.
MolsidomineMolsidomine may increase the hypotensive activities of Alprenolol.
MoricizineMoricizine may increase the hypotensive activities of Alprenolol.
MoxonidineAlprenolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Alprenolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Alprenolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Alprenolol.
NadololAlprenolol may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Alprenolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.
NaproxenNaproxen may decrease the antihypertensive activities of Alprenolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Alprenolol.
NebivololAlprenolol may increase the hypotensive activities of Nebivolol.
NeostigmineNeostigmine may increase the bradycardic activities of Alprenolol.
NepafenacNepafenac may decrease the antihypertensive activities of Alprenolol.
NevirapineThe metabolism of Alprenolol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Alprenolol.
NicardipineNicardipine may increase the hypotensive activities of Alprenolol.
NicorandilAlprenolol may increase the hypotensive activities of Nicorandil.
NicotineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Alprenolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Alprenolol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Alprenolol.
NiguldipineAlprenolol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Alprenolol can be decreased when combined with Nilotinib.
NilvadipineAlprenolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Alprenolol.
NimodipineNimodipine may increase the hypotensive activities of Alprenolol.
NisoldipineNisoldipine may increase the hypotensive activities of Alprenolol.
NitrendipineAlprenolol may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Alprenolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
NorepinephrineAlprenolol may decrease the bronchodilatory activities of Norepinephrine.
ObinutuzumabAlprenolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Alprenolol.
OlanzapineThe serum concentration of Alprenolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Alprenolol.
OlodaterolAlprenolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Alprenolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Alprenolol.
OmapatrilatAlprenolol may increase the hypotensive activities of Omapatrilat.
OrciprenalineAlprenolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Alprenolol.
OuabainAlprenolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Alprenolol.
OxprenololAlprenolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Alprenolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.
PanobinostatThe metabolism of Alprenolol can be decreased when combined with Panobinostat.
ParecoxibParecoxib may decrease the antihypertensive activities of Alprenolol.
PargylineAlprenolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Alprenolol can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololAlprenolol may increase the hypotensive activities of Penbutolol.
PentobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Pentobarbital.
PentoliniumAlprenolol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Alprenolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Alprenolol.
PerindoprilPerindopril may increase the hypotensive activities of Alprenolol.
PerphenazinePerphenazine may increase the hypotensive activities of Alprenolol.
PhenelzinePhenelzine may increase the hypotensive activities of Alprenolol.
PheniprazinePheniprazine may increase the hypotensive activities of Alprenolol.
PhenobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineAlprenolol may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Alprenolol.
PhentolaminePhentolamine may increase the hypotensive activities of Alprenolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Alprenolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
PhenylpropanolamineAlprenolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Alprenolol.
PilocarpineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Alprenolol.
PinacidilAlprenolol may increase the hypotensive activities of Pinacidil.
PindololAlprenolol may increase the hypotensive activities of Pindolol.
PirbuterolAlprenolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Alprenolol.
PirlindolePirlindole may increase the hypotensive activities of Alprenolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Alprenolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Alprenolol.
PolythiazideAlprenolol may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Alprenolol.
PrimaquineThe metabolism of Alprenolol can be decreased when combined with Primaquine.
PrimidoneThe serum concentration of Alprenolol can be decreased when it is combined with Primidone.
ProcaterolAlprenolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Alprenolol.
PromazinePromazine may increase the hypotensive activities of Alprenolol.
PromethazinePromethazine may increase the hypotensive activities of Alprenolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Alprenolol.
PropafenoneThe serum concentration of Alprenolol can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the hypotensive activities of Alprenolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
PTC299PTC299 may decrease the antihypertensive activities of Alprenolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Alprenolol.
QuinaprilAlprenolol may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Alprenolol can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Alprenolol.
RamiprilRamipril may increase the hypotensive activities of Alprenolol.
RanolazineThe metabolism of Alprenolol can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Alprenolol.
RegorafenibRegorafenib may increase the bradycardic activities of Alprenolol.
RemikirenRemikiren may increase the hypotensive activities of Alprenolol.
RescinnamineAlprenolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Alprenolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Alprenolol.
RiociguatAlprenolol may increase the hypotensive activities of Riociguat.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.
RitodrineAlprenolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe metabolism of Alprenolol can be decreased when combined with Ritonavir.
RituximabAlprenolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Alprenolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Alprenolol.
RolapitantThe metabolism of Alprenolol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Alprenolol can be decreased when combined with Ropinirole.
SafrazineSafrazine may increase the hypotensive activities of Alprenolol.
SalbutamolAlprenolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Alprenolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Alprenolol.
SalmeterolAlprenolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Alprenolol.
SaprisartanAlprenolol may increase the hypotensive activities of Saprisartan.
SecobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Alprenolol.
SelexipagAlprenolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Alprenolol.
SertralineThe serum concentration of Alprenolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Alprenolol.
SilodosinAlprenolol may increase the orthostatic hypotensive activities of Silodosin.
SitaxentanAlprenolol may increase the hypotensive activities of Sitaxentan.
SpiraprilAlprenolol may increase the hypotensive activities of Spirapril.
SRT501SRT501 may decrease the antihypertensive activities of Alprenolol.
StiripentolThe metabolism of Alprenolol can be decreased when combined with Stiripentol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Alprenolol.
SulindacSulindac may decrease the antihypertensive activities of Alprenolol.
SuprofenSuprofen may decrease the antihypertensive activities of Alprenolol.
TacrineTacrine may increase the bradycardic activities of Alprenolol.
TadalafilTadalafil may increase the antihypertensive activities of Alprenolol.
TamsulosinAlprenolol may increase the orthostatic hypotensive activities of Tamsulosin.
TelmisartanAlprenolol may increase the hypotensive activities of Telmisartan.
TemocaprilAlprenolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Alprenolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Alprenolol.
TerazosinAlprenolol may increase the orthostatic hypotensive activities of Terazosin.
TerbinafineThe metabolism of Alprenolol can be decreased when combined with Terbinafine.
TerbutalineAlprenolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Alprenolol.
TerlipressinAlprenolol may increase the hypotensive activities of Terlipressin.
TheophyllineAlprenolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThe serum concentration of Alprenolol can be decreased when it is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Alprenolol.
ThiopentalThe serum concentration of Alprenolol can be decreased when it is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Alprenolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Alprenolol.
TiboloneAlprenolol may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Alprenolol can be decreased when combined with Ticlopidine.
TicrynafenAlprenolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Alprenolol.
TipranavirThe metabolism of Alprenolol can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
TolazamideAlprenolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Alprenolol.
TolbutamideAlprenolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Alprenolol.
TolmetinTolmetin may decrease the antihypertensive activities of Alprenolol.
ToloxatoneToloxatone may increase the hypotensive activities of Alprenolol.
TorasemideTorasemide may increase the hypotensive activities of Alprenolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Alprenolol.
TranilastTranilast may decrease the antihypertensive activities of Alprenolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Alprenolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Alprenolol.
TravoprostTravoprost may increase the hypotensive activities of Alprenolol.
TrazodoneThe serum concentration of Alprenolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Alprenolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Alprenolol.
TrichlormethiazideAlprenolol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Alprenolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Alprenolol.
TrimazosinAlprenolol may increase the hypotensive activities of Trimazosin.
TrimethaphanAlprenolol may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Alprenolol.
TubocurarineTubocurarine may increase the bradycardic activities of Alprenolol.
UdenafilUdenafil may increase the antihypertensive activities of Alprenolol.
UnoprostoneAlprenolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Alprenolol.
ValsartanValsartan may increase the hypotensive activities of Alprenolol.
VardenafilVardenafil may increase the antihypertensive activities of Alprenolol.
VareniclineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Varenicline.
VenlafaxineThe metabolism of Alprenolol can be decreased when combined with Venlafaxine.
VilanterolAlprenolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Alprenolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Alprenolol can be increased when it is combined with Vortioxetine.
XylometazolineAlprenolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Alprenolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Alprenolol.
ZileutonZileuton may decrease the antihypertensive activities of Alprenolol.
ZimelidineThe serum concentration of Alprenolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Alprenolol can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Alprenolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Surman AJ, Doggrell SA: Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria. J Cardiovasc Pharmacol. 1993 Jan;21(1):35-9. [PubMed:7678677 ]
  2. De Ponti F, Cosentino M, Costa A, Girani M, Gibelli G, D'Angelo L, Frigo G, Crema A: Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors. Br J Pharmacol. 1995 Apr;114(7):1447-53. [PubMed:7606348 ]
  3. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  4. Brahmadevara N, Shaw AM, MacDonald A: Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol. 2003 Jan;138(1):99-106. [PubMed:12522078 ]
  5. Im MJ, Holzhofer A, Bottinger H, Pfeuffer T, Helmreich EJ: Interactions of pure beta gamma-subunits of G-proteins with purified beta 1-adrenoceptor. FEBS Lett. 1988 Jan 25;227(2):225-9. [PubMed:2828119 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Brodde OE, Wang XL, O'Hara N, Daul A, Schiess W: Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. [PubMed:2439825 ]
  2. Brodde OE, Daul A, Stuka N, O'Hara N, Borchard U: Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity". Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):417-22. [PubMed:2859531 ]
  3. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Millan MJ, Rivet JM, Canton H, Lejeune F, Bervoets K, Brocco M, Gobert A, Lefebvre de Ladonchamps B, Le Marouille-Girardon S, Verriele L, et al.: S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):451-63. [PubMed:1323650 ]
  2. Darmani NA: Role of the inhibitory adrenergic alpha 2 and serotonergic 5-HT1A components of cocaine's actions on the DOI-induced head-twitch response in 5-HT2-receptor supersensitive mice. Pharmacol Biochem Behav. 1993 Jun;45(2):269-74. [PubMed:8392199 ]
  3. Kuipers W, Link R, Standaar PJ, Stoit AR, Van Wijngaarden I, Leurs R, Ijzerman AP: Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. Mol Pharmacol. 1997 May;51(5):889-96. [PubMed:9145928 ]
  4. Misane I, Johansson C, Ogren SO: Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat. Br J Pharmacol. 1998 Oct;125(3):499-509. [PubMed:9806333 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23